

Gabriela Hernandez-Molina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1417055/publications.pdf>

Version: 2024-02-01

85
papers

2,336
citations

304602

22
h-index

233338

45
g-index

90
all docs

90
docs citations

90
times ranked

2999
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 3-18.	0.5	307
2	Exercise for osteoarthritis of the hip. <i>The Cochrane Library</i> , 2014, 2014, CD007912.	1.5	219
3	Effect of therapeutic exercise for hip osteoarthritis pain: Results of a meta-analysis. <i>Arthritis and Rheumatism</i> , 2008, 59, 1221-1228.	6.7	149
4	New Onset of Autoimmune Diseases Following COVID-19 Diagnosis. <i>Cells</i> , 2021, 10, 3592.	1.8	135
5	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1042-1050.	0.5	132
6	The meaning of anti-Ro and anti-La antibodies in primary Sjögren's syndrome. <i>Autoimmunity Reviews</i> , 2011, 10, 123-125.	2.5	106
7	Adipokine Contribution to the Pathogenesis of Osteoarthritis. <i>Mediators of Inflammation</i> , 2017, 2017, 1-26.	1.4	101
8	Central bone marrow lesions in symptomatic knee osteoarthritis and their relationship to anterior cruciate ligament tears and cartilage loss. <i>Arthritis and Rheumatism</i> , 2008, 58, 130-136.	6.7	69
9	Exercise for osteoarthritis of the hip. , 2009, , CD007912.		68
10	Novel autoantibodies in Sjögren's syndrome: A comprehensive review. <i>Autoimmunity Reviews</i> , 2019, 18, 192-198.	2.5	59
11	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , 2020, 59, 2350-2359.	0.9	54
12	Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study. <i>Blood</i> , 2010, 116, 3058-3063.	0.6	52
13	Ottawa Panel evidence-based clinical practice guidelines for therapeutic exercise in the management of hip osteoarthritis. <i>Clinical Rehabilitation</i> , 2016, 30, 935-946.	1.0	50
14	Peripheral regulatory cells immunophenotyping in Primary Sjögren's Syndrome: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2013, 15, R68.	1.6	44
15	Similarities and Differences Between Primary and Secondary Sjögren's Syndrome. <i>Journal of Rheumatology</i> , 2010, 37, 800-808.	1.0	42
16	Chemokine saliva levels in patients with primary Sjögren's syndrome, associated Sjögren's syndrome, pre-clinical Sjögren's syndrome and systemic autoimmune diseases. <i>Rheumatology</i> , 2011, 50, 1288-1292.	0.9	39
17	Autoimmune comorbidity in achalasia patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 203-208.	1.4	31
18	Cytokines and Effector/Regulatory Cells Characterization in the Physiopathology of Cutaneous Lupus Erythematosus: A Cross-Sectional Study. <i>Mediators of Inflammation</i> , 2016, 2016, 1-15.	1.4	30

#	ARTICLE	IF	CITATIONS
19	X chromosome monosomy in primary and overlapping autoimmune diseases. <i>Autoimmunity Reviews</i> , 2012, 11, 301-304.	2.5	28
20	Clinimetric methods in Sjögren's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 627-639.	1.6	27
21	The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 382-8.	0.4	27
22	Coexistence of Amyloidosis and Primary Sjögren's Syndrome: An Overview. <i>Current Rheumatology Reviews</i> , 2018, 14, 231-238.	0.4	26
23	Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. <i>Rheumatology</i> , 2021, 60, 4558-4567.	0.9	24
24	Histopathological environment besides the focus score in Sjögren's syndrome. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 898-903.	0.9	23
25	Midfoot and forefoot osteoarthritis. <i>Foot</i> , 2014, 24, 128-134.	0.4	23
26	Elastographic ultrasound: an additional image tool in Sjögren's syndrome. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1293-1300.	0.9	23
27	The role of the X chromosome in immunity and autoimmunity. <i>Autoimmunity Reviews</i> , 2007, 6, 218-222.	2.5	22
28	Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus. <i>Cytokine</i> , 2019, 119, 95-112.	1.4	21
29	Prevalence and associations of anti-phosphatidylserine/prothrombin antibodies with clinical phenotypes in patients with primary antiphospholipid syndrome. <i>Thrombosis Research</i> , 2019, 174, 141-147.	0.8	19
30	Gout in Renal Allograft Recipients According to the Pretransplant Hyperuricemic Status. <i>Transplantation</i> , 2008, 86, 1543-1547.	0.5	17
31	Markedly high salivary and lacrimal CXCL17 levels in primary Sjögren's syndrome. <i>Joint Bone Spine</i> , 2018, 85, 379-380.	0.8	17
32	Can nailfold videocapillaroscopy images be interpreted reliably by different observers? Results of an inter-reader and intra-reader exercise among rheumatologists with different experience in this field. <i>Clinical Rheumatology</i> , 2019, 38, 205-210.	1.0	17
33	Predicting Sjogren's syndrome in patients with recent-onset SLE. <i>Rheumatology</i> , 2013, 52, 1438-1442.	0.9	16
34	Absence of salivary CCL28 in primary Sjögren's syndrome. <i>Rheumatology International</i> , 2015, 35, 1431-1434.	1.5	16
35	IgG4-Related Disease. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e596-e604.	0.5	16
36	Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjogren's syndrome in patients with systemic autoimmune diseases in the clinical setting. <i>Rheumatology</i> , 2015, 54, 441-448.	0.9	15

#	ARTICLE	IF	CITATIONS
37	SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients. <i>Rheumatology</i> , 2021, 60, 2946-2957.	0.9	15
38	What is the meaning of ANCA positivity in IgG4-related disease?. <i>Rheumatology</i> , 2021, 60, 3845-3850.	0.9	14
39	PPP2R2B hypermethylation causes acquired apoptosis deficiency in systemic autoimmune diseases. <i>JCI Insight</i> , 2019, 4, .	2.3	14
40	Major salivary gland enlargement in IgG4-related disease is associated with multiorgan involvement and higher basal disease activity. <i>Modern Rheumatology</i> , 2020, 30, 172-177.	0.9	13
41	Pan-American League of Associations for Rheumatology (PANLAR) capillaroscopy study group consensus for the format and content of the report in capillaroscopy in rheumatology. <i>Clinical Rheumatology</i> , 2019, 38, 2327-2337.	1.0	12
42	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. <i>Rheumatology</i> , 2022, 62, 243-255.	0.9	12
43	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 166-174.	0.4	12
44	Polyarticular arthritis secondary to <i>Mycobacterium bovis</i> infection: An unusual clinical presentation. <i>Joint Bone Spine</i> , 2007, 74, 107-109.	0.8	11
45	High-resolution HLA analysis of primary and secondary Sjögren's syndrome: a common immunogenetic background in Mexican patients. <i>Rheumatology International</i> , 2015, 35, 643-649.	1.5	11
46	Usefulness of IgA Anti-Î±-fodrin Antibodies in Combination with Rheumatoid Factor and/or Antinuclear Antibodies as Substitute Immunological Criterion in Sjögren Syndrome with Negative Anti-SSA/SSB Antibodies. <i>Journal of Rheumatology</i> , 2016, 43, 1852-1857.	1.0	11
47	IgG4-related kidney disease: experience from a Mexican cohort. <i>Clinical Rheumatology</i> , 2020, 39, 3401-3408.	1.0	11
48	<i>HIF1A</i> (rs11549465) and <i>AKNA</i> (rs10817595) Gene Polymorphisms Are Associated with Primary Sjögren's Syndrome. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	10
49	Perioperative management of patients with antiphospholipid syndrome: a single-center experience. <i>Rheumatology International</i> , 2017, 37, 1159-1164.	1.5	9
50	MicroRNA Expression in Cutaneous Lupus: A New Window to Understand Its Pathogenesis. <i>Mediators of Inflammation</i> , 2019, 2019, 1-26.	1.4	9
51	Risk of Wnt/Î²-catenin signalling pathway gene polymorphisms in primary Sjögren's syndrome. <i>Rheumatology</i> , 2020, 59, 418-425.	0.9	9
52	Hyperviscosity in primary Sjögren's syndrome: clinical implications. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 84-89.	0.9	8
53	Sarcoidosis: a single hospital-based study in a 24-year period. <i>Revista De Investigacion Clinica</i> , 2015, 67, 33-8.	0.2	8
54	Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 503-8.	0.4	8

#	ARTICLE	IF	CITATIONS
55	Serum immunoglobulin free light chains and their association with clinical phenotypes, serology and activity in patients with IgG4-related disease. <i>Scientific Reports</i> , 2021, 11, 1832.	1.6	6
56	Main causes and risk factors for hospitalisation in patients with primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 721-5.	0.4	6
57	Chemokine tear levels in primary Sjögren's syndrome and their relationship with symptoms. <i>International Ophthalmology</i> , 2022, 42, 2355-2361.	0.6	5
58	Autoimmune Thyroid Disease in Primary Sjögren's Syndrome: Real-life Screening Practice and Clinical Outcomes. <i>Current Rheumatology Reviews</i> , 2022, 18, 272-277.	0.4	5
59	Factors influencing the EULAR Sjögren's Syndrome Patient-Reported Index in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 153-158.	0.4	5
60	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. <i>Drugs and Aging</i> , 2021, 38, 265-284.	1.3	4
61	Chronic Destructive Elbow Arthropathy Associated With Hydroxyapatite Crystals in a Patient With Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2006, 12, 194-195.	0.5	3
62	Sjögren's syndrome and pancreatic affection. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 130-134.	0.2	3
63	Biopsy-proven renal involvement and prognosis in 13 hispanic patients with primary Sjögren syndrome. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 43-48.	0.1	3
64	Long-Term Effectiveness of Polymerized-Type I Collagen Intra-Articular Injections in Patients with Symptomatic Knee Osteoarthritis: Clinical and Radiographic Evaluation in a Cohort Study. <i>Advances in Orthopedics</i> , 2020, 2020, 1-9.	0.4	3
65	Thrombosis and thrombocytopenia in antiphospholipid syndrome: their association with mean platelet volume and hematological ratios. <i>Thrombosis Research</i> , 2021, 203, 12-17.	0.8	3
66	Clinical and Serological Features in Latin American IgG4-Related Disease Patients Differ According to Sex, Ethnicity, and Clinical Phenotype. <i>Journal of Clinical Rheumatology</i> , 2022, 28, 285-292.	0.5	3
67	Afección renal confirmada mediante biopsia y pronóstico en 13 pacientes hispanos con síndrome de Sjögren primario. <i>Medicina Clínica</i> , 2018, 150, 43-48.	0.3	2
68	Hughes-Stovin syndrome: an uncommon cause of pulmonary aneurysms. <i>Rheumatology</i> , 2020, 59, 2183-2184.	0.9	2
69	Persistent serological activity in primary Sjögren's syndrome. <i>Clinical Rheumatology</i> , 2020, 39, 919-923.	1.0	2
70	Omega-3 and omega-6 fatty acids in primary Sjögren's syndrome: clinical meaning and association with inflammation. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 34-39.	0.4	2
71	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 85-94.	0.4	2
72	Refractory ascites in systemic lupus erythematosus: further biological support of intraperitoneal steroid treatment as a suitable therapeutic option. <i>Clinical Rheumatology</i> , 2017, 36, 707-711.	1.0	1

#	ARTICLE	IF	CITATIONS
73	Spontaneous cholecystocutaneous fistula as the presenting manifestation of IgG4-related disease. <i>Surgery</i> , 2022, 171, e17-e18.	1.0	1
74	Î±-enolase is an antigenic target in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 29-35.	0.4	1
75	Performance of the 2016 ACR/EULAR SS classification criteria in patients with secondary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 130-133.	0.4	1
76	Differential Th follicular cell subsets in minor salivary glands of patients with primary Sjögren's syndrome and systemic lupus erythematosus associated with Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 49-56.	0.4	1
77	Total body water and sicca symptoms in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	1
78	AB1241â€¦MOST PREVALENT COMORBIDITIES IN PRIMARY SJÖGRENâ€™S SYNDROME IN A HISPANIC POPULATION. , 2019, , .		0
79	Task Force Report on Non-criteria Manifestations: Thrombocytopenia. , 2012, , 195-206.		0
80	Parotid gland swelling in primary Sjögrenâ€™s syndrome: activity and other sialadenosis causes. <i>Rheumatology</i> , 2021, , .	0.9	0
81	Use and withdrawal of immunosuppressors in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 177-181.	0.4	0
82	Factors influencing the EULAR Sjögren's Syndrome Patient Reported Index in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
83	Differential Th follicular cell subsets in minor salivary glands of patients with primary Sjögren's syndrome and systemic lupus erythematosus associated with Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
84	Post-COVID-19 syndrome in patients with primary Sjögren's syndrome after acute SARS-CoV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
85	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 133, 166-174.	0.4	0